Amycretin (Novo Nordisk): The Dual Approach Novo Nordisk, the maker of Ozempic and Wegovy, is developing amycretin, a dual GLP-1 and amylin agonist
Perceived hunger at week 24 decreased by 1.4 to 1.5 points on the Eating Inventory scale across the 4mg, 8mg, and 12mg groups
The concern isn't unfounded: GLP-1 receptor agonists create sustained metabolic shifts that increase oxidative byproducts during fat oxidation, and glutathione is the body's primary intracellular antioxidant
To use the PDF version: just download one, open it in program that can display the PDF file format, and print
Rare but Serious Risks: Serious adverse events are uncommon, but the class has a few important considerations: Pancreatitis: Post-marketing reports linked GLP-1 RAs to cases of acute pancreatitis
in Sex Differences in Cardiovascular Physiology and Pathophysiology (eds LaMarca, B